May 17, 2020

UK PM Theresa May proposes £160mn investment into healthcare research sector

Brexit
Theresa May
healthcare
investment
Jonathan Dyble
2 min
Number ten
In the ever-imminent face of Brexit, the UK government has pledged £160mn to the healthcare and medical research sector, part of Prime Minister Theresa...

In the ever-imminent face of Brexit, the UK government has pledged £160mn to the healthcare and medical research sector, part of Prime Minister Theresa May’s plans for a £4.7bn increase in research and development over the next four years.

In the wake of the announcement, the industry is set to benefit from a more favourable tax policy and increased funding amongst a general policy that will encourage sector growth.

The healthcare and medical research industry was identified as one of five key sectors to the UK economy by May, with almost 235,000 employees and 5,000 companies operating in the sector.

See Also:

The first phase of investment, recommended by the UK’s life sciences industry, will see £146mn invested to support the development of advanced treatments and research by industry SME’s, and help cultivate manufacturing innovation.

The remaining £14mn of the £160mn of funding will go to medical technology research centres, with the aim of enhancing collaboration between private research companies and the National Health Service, with the Life Sciences Industrial Strategy report outlining this as a key goal.

“We have created a strategy which capitalises on our strong science base to further build the industry into a globally-unique and internationally competitive life sciences eco-system,” said Sir John Bell, Chairman of the UK Office for Strategic Coordination of Health Research and the man behind the government-commissioned report.

The move is in line with the government’s broader plans of a modern industrial strategy, designed to boost Britain’s weak productivity growth levels.

Share article

Jun 24, 2021

Data de-identification - why it matters in healthcare

dataprivacy
patientdata
electronicmedicalrecords
datadeidentification
3 min
Riddhiman Das, co-founder and CEO of data privacy startup TripleBlind tells us why data de-identification is important in the healthcare sector

Large amounts of healthcare data is generated yet goes unused due to privacy concerns. To address this, data privacy firm TripleBlind has created Blind De-identification, a new approach that allows healthcare organisations to use patient data while eliminating the possibility of the user learning anything about the patient’s identity. 

We asked Riddhiman Das, co-founder and CEO to tell us more about data de-identification. 

Why is data de-identification important in healthcare? 
Blind De-identification allows every attribute of any given dataset to be used, even at an individual level, while being compliant to privacy laws, rules, and regulations by default.

Governments around the world are adopting global data privacy and residency laws like GDPR, which prohibit citizens’ personally identifiable information data from leaving the borders of the country. While great for data protection, data residency laws result in global silos of inaccessible data. TripleBlind allows computations to be done on enterprise-wise global data, while enforcing data residency regulations. 

In the US, HIPAA compliance has relied on what is called the Safe Harbor method, which requires removing 18 types of personal patient identifiers like names, email addresses, and medical record numbers. The Safe Harbor method can be too restrictive with the data or can leave too many indirect identifiers, which puts the patient data security at risk. Getting de-identification wrong could make an organisation liable for a costly mistake.

What does TripleBlind's solution do? 
With TripleBlind, data is legally de-identified in real time with practically 0% probability of re-identification. Our solution allows analytics on data containing personally identifiable information and protected health information  with zero possibility of re-identifying an individual from the dataset. This allows healthcare organisations to access more meaningful data, creating more accurate and less biased results.

For example, a healthcare drug researcher in a rural, predominantly white area, would only have patient data that would reflect their local population. With TripleBlind’s de-identification, they could more easily leverage third-party data from another healthcare facility in a more diverse region, creating a more complete data set that more accurately reflects the larger population. This has the possibility to create more accurate diagnoses and better drug results for more diverse populations.

How can healthcare organisations use this in practice? 
TripleBlind is blind to all data and algorithms. That means we never take possession of customer data. We only route traffic between entities, enforce permissions, and provide audit trails. The enterprise’s data remains under their control. TripleBlind does not host, copy or control their data, algorithms or other information assets, ever. 

We facilitate a connection to an encrypted version of their information assets. Our technology allows the algorithms and data to interact in an encrypted space that only exists for the duration of the operation. Organisations use their existing infrastructure, so it’s not hardware dependent.

Share article